The University of Chicago Header Logo

Connection

Rudolph Navari to Antineoplastic Agents

Back to Details
This is a "connection" page, showing publications Rudolph Navari has written about Antineoplastic Agents.
Rudolph Navari
Connection Strength
7.149
Antineoplastic Agents
  1. Olanzapine With or Without Fosaprepitant for Preventing Chemotherapy Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy: A Phase III Randomized, Double-Blind, Placebo-Controlled Trial (ALLIANCE A221602). Oncologist. 2023 08 03; 28(8):722-729.
    View in: PubMed
    Score: 0.397
  2. Real-World Treatment Outcomes, Healthcare Resource Use, and Costs Associated with Antiemetics Among Cancer Patients on Cisplatin-Based Chemotherapy. Adv Ther. 2023 07; 40(7):3217-3226.
    View in: PubMed
    Score: 0.392
  3. Duration of Chemotherapy-Induced Nausea and Vomiting (CINV) as a Predictor of Recurrent CINV in Later Cycles. Oncologist. 2023 03 17; 28(3):208-213.
    View in: PubMed
    Score: 0.387
  4. Single-dose netupitant/palonosetron versus 3-day aprepitant for preventing chemotherapy-induced nausea and vomiting: a pooled analysis. Future Oncol. 2021 Aug; 17(23):3027-3035.
    View in: PubMed
    Score: 0.339
  5. Avoidable Acute Care Use Associated with Nausea and Vomiting Among Patients Receiving Highly Emetogenic Chemotherapy or Oxaliplatin. Oncologist. 2021 04; 26(4):325-331.
    View in: PubMed
    Score: 0.331
  6. Unscheduled hydrations: redefining complete response in chemotherapy-induced nausea and vomiting studies. Future Oncol. 2020 Aug; 16(24):1863-1872.
    View in: PubMed
    Score: 0.320
  7. Safety of Polysorbate 80 in the Oncology Setting. Adv Ther. 2018 Jun; 35(6):754-767.
    View in: PubMed
    Score: 0.277
  8. Management of Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients. Paediatr Drugs. 2017 Jun; 19(3):213-222.
    View in: PubMed
    Score: 0.259
  9. Rolapitant hydrochloride: prophylactic treatment for chemotherapy-induced nausea and vomiting. Drugs Today (Barc). 2016 Aug; 52(8):431-438.
    View in: PubMed
    Score: 0.244
  10. Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. N Engl J Med. 2016 Jul 14; 375(2):134-42.
    View in: PubMed
    Score: 0.244
  11. Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting. N Engl J Med. 2016 Apr 07; 374(14):1356-67.
    View in: PubMed
    Score: 0.239
  12. Treatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and Vomiting. Biomed Res Int. 2015; 2015:595894.
    View in: PubMed
    Score: 0.229
  13. Palonosetron for the treatment of chemotherapy-induced nausea and vomiting. Expert Opin Pharmacother. 2014 Dec; 15(17):2599-608.
    View in: PubMed
    Score: 0.216
  14. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer. 2013 Jun; 21(6):1655-63.
    View in: PubMed
    Score: 0.191
  15. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol. 2011 Sep-Oct; 9(5):188-95.
    View in: PubMed
    Score: 0.175
  16. Antiemetic control: toward a new standard of care for emetogenic chemotherapy. Expert Opin Pharmacother. 2009 Mar; 10(4):629-44.
    View in: PubMed
    Score: 0.146
  17. Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Expert Rev Anticancer Ther. 2008 Nov; 8(11):1733-42.
    View in: PubMed
    Score: 0.143
  18. Treatment of depressive symptoms in patients with early stage breast cancer undergoing adjuvant therapy. Breast Cancer Res Treat. 2008 Nov; 112(1):197-201.
    View in: PubMed
    Score: 0.134
  19. Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Expert Opin Investig Drugs. 2007 Dec; 16(12):1977-85.
    View in: PubMed
    Score: 0.134
  20. A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study. Support Care Cancer. 2007 Nov; 15(11):1285.
    View in: PubMed
    Score: 0.128
  21. Prevention of emesis from multiple-day and high-dose chemotherapy regimens. J Natl Compr Canc Netw. 2007 Jan; 5(1):51-9.
    View in: PubMed
    Score: 0.126
  22. New approaches to chemotherapy-induced nausea and vomiting: from neuropharmacology to clinical investigations. Cancer J. 2006 Sep-Oct; 12(5):341-7.
    View in: PubMed
    Score: 0.123
  23. Emerging drugs for chemotherapy-induced emesis. Expert Opin Emerg Drugs. 2006 Mar; 11(1):137-51.
    View in: PubMed
    Score: 0.119
  24. A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study. Support Care Cancer. 2005 Jul; 13(7):529-34.
    View in: PubMed
    Score: 0.110
  25. Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting. Expert Rev Anticancer Ther. 2004 Oct; 4(5):715-24.
    View in: PubMed
    Score: 0.108
  26. Role of neurokinin-1 receptor antagonists in chemotherapy-induced emesis: summary of clinical trials. Cancer Invest. 2004; 22(4):569-76.
    View in: PubMed
    Score: 0.102
  27. 2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting. Support Care Cancer. 2023 Dec 18; 32(1):36.
    View in: PubMed
    Score: 0.102
  28. Single-dose NEPA versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Cancer Med. 2023 08; 12(15):15769-15776.
    View in: PubMed
    Score: 0.099
  29. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents. J Support Oncol. 2003 Jul-Aug; 1(2):89-103.
    View in: PubMed
    Score: 0.099
  30. Olanzapine 5 mg vs 10 mg for the prophylaxis of chemotherapy-induced nausea and vomiting: a network meta-analysis. Support Care Cancer. 2022 Feb; 30(2):1015-1018.
    View in: PubMed
    Score: 0.089
  31. Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature. Support Care Cancer. 2021 Jul; 29(7):3439-3459.
    View in: PubMed
    Score: 0.083
  32. Safety profile of HTX-019 administered as an intravenous push in cancer patients: a retrospective review. Expert Opin Drug Saf. 2020 Feb; 19(2):205-210.
    View in: PubMed
    Score: 0.077
  33. The safety of rolapitant for the treatment of nausea and vomiting associated with chemotherapy. Expert Opin Drug Saf. 2019 Dec; 18(12):1127-1132.
    View in: PubMed
    Score: 0.076
  34. Do we still need to study palonosetron for chemotherapy-induced nausea and vomiting? A cumulative meta-analysis. Crit Rev Oncol Hematol. 2019 Oct; 142:164-186.
    View in: PubMed
    Score: 0.075
  35. Managing Nausea and Vomiting in Patients With Cancer: What Works. Oncology (Williston Park). 2018 03 15; 32(3):121-5, 131, 136.
    View in: PubMed
    Score: 0.068
  36. 2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting. Support Care Cancer. 2017 01; 25(1):303-308.
    View in: PubMed
    Score: 0.062
  37. Olanzapine for Chemotherapy-Induced Nausea and Vomiting. N Engl J Med. 2016 10 06; 375(14):1396.
    View in: PubMed
    Score: 0.062
  38. 2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy. Support Care Cancer. 2017 01; 25(1):277-288.
    View in: PubMed
    Score: 0.061
  39. Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis. Support Care Cancer. 2016 May; 24(5):2381-2392.
    View in: PubMed
    Score: 0.059
  40. The safety of antiemetic medications for the prevention of chemotherapy-induced nausea and vomiting. Expert Opin Drug Saf. 2016; 15(3):343-56.
    View in: PubMed
    Score: 0.059
  41. Efficacy and safety of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) as reported in phase I and II studies: a systematic review. Support Care Cancer. 2016 Feb; 24(2):1001-1008.
    View in: PubMed
    Score: 0.058
  42. Rolapitant for the treatment of chemotherapy-induced nausea and vomiting. Expert Rev Anticancer Ther. 2015; 15(10):1127-33.
    View in: PubMed
    Score: 0.057
  43. 5-HT3 receptors as important mediators of nausea and vomiting due to chemotherapy. Biochim Biophys Acta. 2015 Oct; 1848(10 Pt B):2738-46.
    View in: PubMed
    Score: 0.056
  44. Clinical roundtable monograph: New data in emerging treatment options for chemotherapy-induced nausea and vomiting. Clin Adv Hematol Oncol. 2014 Mar; 12(3 Suppl 9):1-14; quiz 15.
    View in: PubMed
    Score: 0.052
  45. The current status of the use of palonosetron. Expert Opin Pharmacother. 2013 Jul; 14(10):1281-4.
    View in: PubMed
    Score: 0.049
  46. Palonosetron: a second generation 5-hydroxytryptamine 3 receptor antagonist. Expert Opin Drug Metab Toxicol. 2009 Dec; 5(12):1577-86.
    View in: PubMed
    Score: 0.038
  47. Pharmacological management of chemotherapy-induced nausea and vomiting: focus on recent developments. Drugs. 2009; 69(5):515-33.
    View in: PubMed
    Score: 0.036
  48. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869. Cancer. 2002 Jun 01; 94(11):3032-41.
    View in: PubMed
    Score: 0.023
  49. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer. 2002 Jan 01; 94(1):25-36.
    View in: PubMed
    Score: 0.022
  50. Should palonosetron be a preferred 5-HT3 receptor antagonist for chemotherapy-induced nausea and vomiting? An updated systematic review and meta-analysis. Support Care Cancer. 2018 Aug; 26(8):2519-2549.
    View in: PubMed
    Score: 0.017
  51. Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populations. Drug Des Devel Ther. 2017; 11:2621-2629.
    View in: PubMed
    Score: 0.016
  52. Prevention of acute emesis in cancer patients following high-dose cisplatin with the combination of oral dolasetron and dexamethasone. J Clin Oncol. 1997 May; 15(5):2135-8.
    View in: PubMed
    Score: 0.016
  53. Efficacy and safety of different doses of granisetron for the prophylaxis of cisplatin-induced emesis. Support Care Cancer. 1997 Jan; 5(1):31-7.
    View in: PubMed
    Score: 0.016
  54. A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study. Cancer Invest. 2004; 22(3):383-8.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.